Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CANSF - WILLOW BIOSCIENCES INC
Market Cap 10.87M P/E - EPS this Y 70.60% Ern Qtrly Grth -
Income -8.7M Forward P/E - EPS next Y - 50D Avg Chg -7.00%
Sales 1.84M PEG - EPS past 5Y - 200D Avg Chg -3.00%
Dividend N/A Price/Book 0.88 EPS next 5Y - 52W High Chg -36.00%
Recommedations 2.00 Quick Ratio 0.42 Shares Outstanding 144.20M 52W Low Chg 44.00%
Insider Own 24.34% ROA -74.79% Shares Float 112.09M Beta 1.12
Inst Own 0.10% ROE -212.20% Shares Shorted/Prior -/- Price 0.08
Gross Margin -178.04% Profit Margin - Avg. Volume 19,270 Target Price 2.00
Oper. Margin -140.94% Earnings Date Nov 12 Volume 21,390 Change 4.75%
Healthcare | Drug Manufacturers - Specialty & Generic | Canada
About WILLOW BIOSCIENCES INC

Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has a collaboration agreement with SUANFARMA to develop anti-infective API through precision fermentation; and a multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.

WILLOW BIOSCIENCES INC News
11/18/24 WILLOW ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $2.0 MILLION
11/15/24 Willow Biosciences Third Quarter 2024 Earnings: CA$0.01 loss per share (vs CA$0.018 loss in 3Q 2023)
11/12/24 WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
11/07/24 WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
09/18/24 WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
09/05/24 WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.
08/12/24 WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
08/07/24 WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY
07/26/24 WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
07/18/24 WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS
06/26/24 WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM
06/03/24 WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $3.0 MILLION
05/30/24 WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS
05/13/24 WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
03/31/24 Willow Biosciences Full Year 2023 Earnings: CA$0.10 loss per share (vs CA$0.12 loss in FY 2022)
03/28/24 WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
02/29/24 WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC
02/20/24 WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS
01/31/24 WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
01/16/24 WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS